Tokyo, May 18 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000061607) titled 'Observational Study on Adherence to Anamorelin and Changes in Quality of Life in Pancreatic Cancer Patients with Cachexia' on May 18.
Study Type:
Observational
Primary Sponsor:
Institute - Japanese Foundation for Cancer Research
Condition:
Condition - Pancreatic Cancer with Cachexia
Classification by malignancy - Malignancy
Genomic information - NO
Objective:
Narrative objectives1 - The purpose of this study is to evaluate longitudinal changes in medication adherence and health-related quality of life over 24 weeks in pancreatic cancer patients with cachexia receiving anamorelin. Medication adherence will be assessed using CubixxDT (Japanese version) and the Beliefs about Medicines Questionnaire (BMQ), while health-related quality of life will be evaluated using FAACT ACS and EQ-5D-5L.
Basic objectives2 - Others
Eligibility:
Age-lower limit - 18
years-old
<=
Age-upper limit - Not applicable
Gender - Male and Female
Key inclusion criteria - 1.Diagnosed with pancreatic cancer
2.Initiating anamorelin treatment for cancer cachexia
3.Age 18 years or older at registration
4.Written informed consent obtained
Key exclusion criteria - 1.Unable to independently remove anamorelin tablets dispensed with CubixxDT Japanese version
2.Difficulty participating due to clinically significant psychiatric or neurological symptoms
3.Severe cognitive impairment
4.Native language is not Japanese
5.Unable to use ePRO
Target Size - 50
Recruitment Status:
Recruitment status - Preinitiation
Date of protocol fixation - 2026 Year 05 Month 18 Day
Anticipated trial start date - 2026 Year 06 Month 01 Day
Last follow-up date - 2029 Year 04 Month 30 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000070487
Disclaimer: Curated by HT Syndication.
